Courier Capital LLC Sells 1,885 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Courier Capital LLC reduced its shares in Thermo Fisher Scientific by 25.9% in the second quarter, selling 1,885 shares and now holding 5,400 shares worth approximately $2.19 million.
• Thermo Fisher's latest earnings showed an EPS of $5.36, exceeding expectations, with revenue of $10.86 billion, reflecting a 2.9% year-over-year increase.
• Institutional investors own 89.23% of Thermo Fisher's stock, with various hedge funds increasing their stakes in the company during the second quarter.

Courier Capital LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,400 shares of the medical research company's stock after selling 1,885 shares during the quarter. Courier Capital LLC's holdings in Thermo Fisher Scientific were worth $2,190,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Boston Trust Walden Corp grew its holdings in shares of Thermo Fisher Scientific by 23.0% in the second quarter. Boston Trust Walden Corp now owns 2,522 shares of the medical research company's stock valued at $1,023,000 after purchasing an additional 471 shares in the last quarter. Wilson Asset Management International PTY Ltd. grew its stake in shares of Thermo Fisher Scientific by 20.0% in the 2nd quarter. Wilson Asset Management International PTY Ltd. now owns 31,645 shares of the medical research company's stock worth $12,831,000 after buying an additional 5,267 shares in the last quarter. Morningstar Investment Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $1,030,000. Axxcess Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.5% in the 2nd quarter. Axxcess Wealth Management LLC now owns 24,817 shares of the medical research company's stock valued at $10,063,000 after acquiring an additional 1,069 shares during the last quarter. Finally, Community Bank N.A. increased its stake in Thermo Fisher Scientific by 20.1% during the second quarter. Community Bank N.A. now owns 5,312 shares of the medical research company's stock worth $2,154,000 after acquiring an additional 890 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $525.08 on Wednesday. The company has a market capitalization of $198.28 billion, a P/E ratio of 30.37, a P/E/G ratio of 2.85 and a beta of 0.77. The company's 50-day simple moving average is $491.00 and its two-hundred day simple moving average is $448.20. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TMO shares. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a report on Wednesday, October 8th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a report on Tuesday, October 7th. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Finally, Raymond James Financial restated an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $589.10.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.